Expert insights on EU MDR, IVDR, UKRP, FDA compliance, and digital transformation in medical device regulation. Stay ahead of regulatory changes with our analysis and practical guidance.
102 articles
The EU just published fresh harmonised standards for MDR and IVDR—while Greenlight Guru became the first eQMS vendor with ISO 42001 AI certification. Here's what both mean for your compliance stack.
BrightHeart's prenatal AI platform just secured CE Mark under IVDR, while Edwards' LAA clip approval sets up a three-way FDA battle. Both signal regulatory expectations shifting fast.
Heartfelt Technologies' FDA breakthrough designation for AI-powered home heart failure monitoring reveals what regulators are prioritising—and what RA teams need in their evidence packages now.
Spotlight Medical and BrightHeart just secured IVDR CE marks for AI diagnostics. For SaMD teams, these approvals reveal a unified pathway—and new expectations.
BrightHeart's prenatal AI platform just cleared CE Mark, while FDA and MHRA deepen their liaison on software devices. For RA teams, these aren't separate stories—they're a unified message.
AI is no longer optional for MedTech supply chains or QMS workflows. New insights show how AI-driven adaptability and post-market design loops separate reactive teams from those scaling compliance.
Zoll's FDA warning letter and Hologic's breast biopsy needle shortage reveal a common thread: quality gaps ripple across the entire MedTech ecosystem.
A new FDA–MHRA liaison programme and renewed focus on continuous clinical evidence signal a fundamental shift in how software devices will be regulated across borders.
As FDA shifts toward continuous oversight and one-day inspections, manufacturers clinging to 'pre-audit scrambles' risk more than citations—they're losing speed to market.
The MHRA is accelerating AI in healthcare with new sandboxes and public insight. For software medical device teams, this means ISO 14971 just became mission-critical.
Medtronic's Hugo platform demonstrates how device complexity intersects with clinical evaluation rigour. Here's what your EU MDR strategy needs now.
Clinical evaluation has shifted from box-ticking to the cornerstone of EU MDR compliance. Here's what rigorous post-market vigilance teaches us.
From 28 May 2026, EUDAMED's first four modules became mandatory. Combined with MDR revision talks, the regulatory landscape just shifted—here's what changes.
A new AI tool estimating childhood ADHD risk highlights the regulatory complexity of predictive diagnostics. Here's what device manufacturers need to consider now.
FDA's shifting stance on algorithmic transparency and a major recall underscore a new reality: if your AI medical device can't explain itself, it won't clear regulatory hurdles—or survive post-market.
As ISO 13485 guidance clarifies software production controls, Insulet's 7M device recall shows why rigorous QMS discipline matters—even for established players.
MHRA's heatwave warning isn't just about medicines. For medical device manufacturers, it's a reminder that environmental storage conditions are a post-market surveillance blind spot.
Medtronic's €60m Dublin investment reveals how major players are positioning for EU digital health regulations. Here's what smaller manufacturers should learn.
FDA's AI predetermined change control plans are exposing quality gaps now. Meanwhile, regulatory frameworks are shifting in the UK and EU—here's what to prioritise.
Natera's Signatera CDx marks a watershed for personalised diagnostics. For device manufacturers, the approval pathway offers critical lessons in evidence generation.
MHRA's Vyjuvek approval signals accelerated gene therapy pathways, while overlooked radio equipment rules trip up device makers. Both demand immediate attention.
New approaches to IEC 62304 compliance mean Jira and GitHub aren't just development tools anymore—they're becoming the source of truth for your Design History File.
The FDA's shift to one-day inspections and internal AI expansion signals a fundamental change in regulatory oversight. Here's what it means for your compliance strategy.
The MHRA's latest consultation signals a pivotal shift in UK medical device regulation. Here's what manufacturers and RA teams need to know now.
New guidance reveals the real reason clinical evaluation fails under EU MDR—and it's not lack of effort. Understanding what the regulation actually demands changes everything.
MedTech Europe backs the Commission's regulatory overhaul while flagging critical gaps. Here's what manufacturers need to understand about the incoming changes.
Medtronic's CE Mark for Stealth AXiS and enVVeno's IDE approval reveal diverging regulatory timelines. Here's what product teams need to understand now.
The FDA's Purolea warning letter reveals how AI misuse triggers enforcement, while MHRA's digital transformation signals faster, data-driven oversight.
The FDA's Purolea warning letter isn't about AI—it's about validation. As devices reach market faster, the real challenge begins with post-market maturity.
CMS and FDA's new coverage pathway changes the game for Breakthrough Devices. Here's what your regulatory and commercialisation teams need to know now.
New FDA AI lifecycle guidance and faster Medicare coverage are reshaping the regulatory landscape for software medical devices. Here's what device teams need to know now.
The MHRA is modernising AI regulation while the public demands stronger oversight. For device manufacturers, the message is clear: your QMS needs to evolve now.
AliveCor's CE Mark for an AI-powered 12-lead ECG signals a new regulatory benchmark. Here's what device manufacturers need to know about AI certification under EU MDR.
The FDA is simultaneously tightening clinical trial disclosure requirements and issuing warning letters for quality lapses. These parallel enforcement actions signal a regulatory environment where transparency and compliance can't be siloed.
Three major vascular device approvals in one week reveal strategic regulatory pathways. What endovascular teams need to know about dual-market submissions.
MHRA's consultation on indefinite CE mark recognition signals a major policy shift, while FDA's MDUFA VI staffing pledge reshapes transatlantic market access strategy.
The MHRA's consultation on indefinite CE mark recognition signals a major strategic shift. Here's what regulatory teams need to understand about dual pathways.
The FDA's new PPI guidance marks a fundamental shift in how we build regulatory strategies. For device manufacturers, this isn't optional—it's foundational.
Philips' FDA clearance for AI-guided imaging shows the commercial reality of software-as-medical-device. Getting classification right from day one matters more than ever.
With mandatory EUDAMED compliance just weeks away, many manufacturers remain unprepared. Here's what readiness actually requires—and what happens if you miss it.
Cairn Surgical's 'De Novo 510(k)' application reveals persistent confusion in FDA pathways—and highlights strategic choices every novel device team must get right.
Two recent FDA approvals reveal strategic pathways through PMA and 510(k) routes. Here's what device manufacturers need to understand about evidence standards.
As MHRA and NICE promise faster approvals, Intuitive's recall reveals the regulatory tightrope. What does accelerated market access mean for your post-market surveillance strategy?
As device interoperability gains traction, a parallel QMS challenge emerges. Understanding the connection could define your compliance strategy this year.
The FDA has retired QSIT after decades and launched risk-based inspections under QMSR. Here's what changed on February 2nd and how to prepare your team.
MiniMed's CE Mark for cross-manufacturer sensor integration offers a regulatory roadmap—while Advita's warning letter shows what happens when fundamentals fail.
ReVision's breakthrough designation highlights a truth many overlook: innovative tech means nothing if human factors engineering isn't embedded early.
Two recent AI device clearances highlight FDA's evolving SaMD pathway, while MDUFA VI negotiations expose industry frustrations with review timelines and transparency.
Boston Scientific just secured CE mark expansion for Farapulse in persistent AFib—a significant win that highlights both the power of PFA technology and critical regulatory pathway lessons for innovators.
Abbott's CardioMEMS update shows FDA prioritising real-world usability. As MHRA pauses the Pathways trial, both stories reveal how human factors are reshaping approval pathways.
MedTech regulatory teams are shifting from document-heavy workflows to AI-powered predictive systems in 2025. Modular content libraries, structured claims management, and machine learning transform MLR reviews while reducing submission timelines. Traditional static approaches create bottlenecks as patent cliffs drive faster launches across multiple jurisdictions.
A breakthrough AI diagnostic passes FDA review but triggers high-risk classification in Europe. The same algorithm, trained on global datasets, is rejected by China's regulators. As AI medical device rules fracture across borders, SaMD startups discover that regulatory approval in one market guarantees nothing elsewhere.
Fragmented guidance documents, trial outcomes, and device data don’t just slow down strategy—they distort it. When regulatory plans ignore the full picture, startups risk repeating errors or overlooking key signals. Smart teams are connecting the dots before their next submission is even in draft.
Submission timelines don’t stop at approval. When regulatory frameworks shift mid-cycle or rationale documents vanish with a departing team member, what’s left behind is risk. Discover how MedTech startups can design regulatory systems that adapt, retain context, and strengthen every future interaction with regulators.
Context switching costs MedTech regulatory teams weeks per submission cycle as professionals lose 23 minutes of focus with each system jump. New cognitive research explains why fragmented workflows between PDFs, databases, and email threads increase stress 67% while reducing strategic clarity. The $450 billion productivity crisis is rooted in how the human brain processes regulatory information.
Medical device companies risk losing vital regulatory knowledge when employees leave. To address this, leading MedTech firms implement institutional memory systems that preserve and share regulatory intelligence, streamlining submissions to bodies like the FDA and EMA. This approach reduces compliance risks and fosters innovation, creating a competitive edge in the industry.
The billion-dollar question haunting every medical device startup: Can we finally build one quality system for both sides of the Atlantic? The FDA's new QMSR and the EU MDR both reference ISO 13485, creating a misleading impression of regulatory harmony. Startups treating these systems as interchangeable often face compliance catastrophes, inspection delays, and documentation disasters that can torpedo market launches before they even begin.
Global regulators are converging on how they evaluate AI and software in medical devices. The IMDRF’s 2025 guidance, FDA-EMA alignment, and new international standards are redefining what compliance means—shaping U.S. submissions and timelines for global startups entering the MedTech market.
MedTech startups balancing global growth and compliance face a critical challenge: how to move fast without regulatory missteps. With limited resources and shifting guidance, AI-powered tools offer startup-specific solutions that prioritize only what’s relevant, align with risk tolerance, and enable speed without sacrificing accuracy or global readiness.
U.S. Food and Drug Administration (FDA) cybersecurity guidance 2025 transforms medical device submissions with mandatory SBOMs, threat models, and architecture documentation. Poor cybersecurity hygiene triggers automatic rejections under Section 524B authority. AI-powered regulatory systems provide the traceability that traditional methods cannot achieve.
Outdated manual processes are hindering the ability of MedTech startups to achieve success in regulatory compliance. As the industry evolves and regulatory requirements become increasingly complex, these traditional methods can lead to delays and inefficiencies. The most effective strategies center on integrated tools, human oversight, and scalable systems built for modern regulatory demands.
Fragmented folders and outdated tools are hindering regulatory teams' efficiency. MedTech leaders are changing the game by implementing structured intelligence systems to minimize submission delays, lower compliance risks, and transform guidance overload into a growth strategy. Here’s how the top performers are gaining an advantage.
Regulatory professionals struggle with overwhelming FDA, EMA, and MHRA data that never translates into actionable strategies. Smart MedTech teams systematically transform fragmented regulatory intelligence into predictive submission roadmaps, accelerating approvals and gaining a competitive advantage. Strategic frameworks transform compliance chaos into market domination by analyzing proven global regulatory precedents.
Legacy folder systems weren’t built for the pace or complexity of modern MedTech. When regulatory updates hit, disconnected documents and outdated storage slow everything down. Project-based organization turns fragmented guidance into actionable strategy, built for how teams actually work.
MedTech startups waste millions on preventable clinical trial failures while competitor intelligence sits in plain sight. For each trial amendment, startups may face six-figure costs; yet, most companies overlook the goldmine of regulatory insights available in public databases. AI-powered competitive analysis transforms trial design, slashes development costs, and accelerates FDA approvals for forward-thinking startups.
Regulatory guidance document overload is crushing MedTech startups with 190+ new FDA documents in 2023 alone. While the majority of companies rely on fragmented spreadsheets and email folders. While many teams still rely on fragmented tools, such as spreadsheets and email folders, to manage updates, forward-looking startups are building centralized regulatory intelligence systems that streamline compliance and accelerate submissions.
When regulatory knowledge remains trapped in information silos across individual drives and email folders, MedTech startups face compliance risks that derail market entry. Collaborative regulatory intelligence systems eliminate person-dependent workflows, break down silos, preserve institutional memory, and accelerate submissions.
Traditional search tools fail regulatory professionals with irrelevant results and fragmented data, increasing compliance costs for medical device companies. Purpose-built regulatory intelligence platforms transform global compliance work, reduce operational expenses, and accelerate time-to-market. AI-enhanced solutions move regulatory teams beyond document retrieval to answer extraction in today's complex regulatory landscape.
Regulatory blind spots are silently killing MedTech innovation timelines. While thousands of successful submissions hold strategic gold, teams waste 15+ hours weekly hunting through fragmented databases and outdated folders. Discover how transforming static records into dynamic regulatory intelligence can slash review cycles, neutralize compliance risks, and turn regulatory precedents into your most powerful competitive advantage in 2025.
Regulatory disarray is quietly derailing MedTech innovation. As guidance documents multiply and submission timelines slip, startups face mounting risk from scattered research, outdated precedents, and fragmented workflows. See how early-stage teams can reclaim time, reduce costs, and turn regulatory clarity into a competitive edge in 2025.
Women’s health is a $1T opportunity—but MedTech startups face evolving regulatory hurdles. From FDA and EU MDR classification to data privacy gaps in FemTech, learn how to navigate compliance, leverage fast-track approvals, and build smarter strategies for fertility, menopause, and diagnostic innovations.
A new frontier in connected health is emerging as IoT-powered medical devices revolutionize how care is delivered, monitored, and scaled across the globe. Explore how startups can turn innovation into impact by mastering the regulatory, cybersecurity, and compliance hurdles that shape access to markets—and unlock the full potential of real-time data, remote monitoring, and secure digital ecosystems.
A new era of connected care is unfolding as cloud-powered medical devices transform diagnostics, remote monitoring, and patient outcomes worldwide. Unpack the regulatory, cybersecurity, and quality challenges startups must overcome to thrive, while unlocking the global potential of real-time data, AI, and resilient digital infrastructure.
Global MedTech startups face a turning point in 2025, navigating tariffs, shifting capital, and AI-driven disruption. With personalized medicine on the rise and regulatory landscapes evolving, founders equipped with smart supply chains, strong IP, and digital agility are redefining what it means to scale in uncertain times.
Navigating AI regulation in MedTech is complex, but startups that align early with evolving frameworks can move faster and smarter. By leveraging the FDA’s AI/ML Action Plan, the EU AI Act, and global regulatory programs, companies can accelerate approvals, reduce risk, and scale confidently. See how leading startups are turning compliance into a strategic advantage.
In the high-stakes world of medical device innovation, success isn't about waiting for the right moment—it's about creating it. Discover how medical device startups can leverage 2025 M&A trends to attract investment, form strategic partnerships, and build toward successful exits. Learn why regulatory readiness, clean capital structures, and targeted innovation in high-growth segments like cardiovascular and neurology are key to standing out in today’s MedTech landscape. Are you ready to architect your startup's strategic future?
Expanding a medical device startup globally is challenging, but regulatory harmonization offers a faster path to market. By leveraging the Medical Device Single Audit Program (MDSAP) and Mutual Recognition Agreements (MRAs), startups can streamline approvals, reduce compliance costs, and enter multiple markets efficiently. Learn how leading medical device companies are using these strategies to scale faster.
Digital therapeutics startups face a regulatory maze that determines their success or failure. Navigate Germany's DiGA fast-track, overcome U.S. reimbursement barriers, and tap into a $20 billion market opportunity. This 5-step roadmap transforms compliance challenges into competitive advantages for founders ready to disrupt healthcare.
Unlock the secrets of Remote Patient Monitoring (RPM) compliance. Learn how medical device startups can navigate FDA, EU MDR, and UK regulations to transform innovative RPM technologies into market-ready solutions that revolutionize at-home healthcare.
Medical device startups face a cybersecurity reckoning—regulations are tightening, threats are escalating, and one breach could end it all. FDA and EU MDR now demand security by design, but most startups still lag behind. Get ahead before it's too late—here’s how to build a compliance-driven, cyber-resilient future.
Sustainable innovation is transforming medical device startups, helping them navigate evolving regulations while unlocking new market opportunities. By integrating eco-friendly design, circular economy principles, and compliance with EU and UK sustainability mandates, startups can reduce risks, attract investors, and drive long-term success in the healthcare industry.
Many startups view post-market surveillance (PMS) as compliance, but it’s a growth driver. Leverage real-world data for smarter products, faster market expansion, and a competitive edge. Unlock AI-driven insights and proactive feedback to innovate, improve patient outcomes, and stay ahead of regulatory changes. Turn PMS into a catalyst for success.
Determine how to navigate the FDA’s Refuse-to-Accept (RTA) policy and avoid costly 510(k) submission delays. Identify the top five pitfalls that lead to rejection and discover expert strategies to streamline approval. Gain insights on cybersecurity compliance, documentation best practices, and key review milestones to ensure a smooth FDA submission process.
Master the art of risk management to drive your medical device startup to success. Harness the power of ISO 14971 to enhance safety, streamline compliance, and build trust. Explore 2024’s innovations, including AI-powered tools, real-time monitoring, advanced cybersecurity, and next-level post-market surveillance. Gain actionable strategies to create safer, market-ready devices with confidence.
Explore the role of an EU Authorised Representative and why it's essential for non-EU medical device manufacturers seeking market access in Europe. Learn about key responsibilities, potential risks of non-compliance, and how SMEDTEC offers tailored solutions to navigate MDR/IVDR regulations, ensuring seamless compliance and long-term success in the EU market.
Regulatory non-compliance silently bankrupts medical device startups every year. See how proactive Quality Management Systems (QMS) and Post Market Surveillance (PMS) can save your startup time, money, and reputation. Real case studies, actionable strategies, and expert insights for MedTech success.
Navigating the regulatory maze can make or break a medtech startup. Discover how a proactive regulatory strategy can transform roadblocks into opportunities, helping you secure faster product approvals, attract investors, and gain a competitive edge in the global market. From leveraging expedited pathways to aligning compliance with business goals, this guide equips startups with the tools to thrive in an ever-evolving healthcare landscape.
Learn how medical device startups can streamline regulatory operations with scalable processes. Explore strategies for submission planning, document control, and post-market compliance while leveraging AI and QMS tools to enhance efficiency, ensure compliance, and support sustainable growth.
Adopting a rigid Quality Management System (QMS) for medical device startups is like trying to run a sprint in oversized boots—it slows you down, wastes energy, and makes you less competitive. While l
Real-world evidence (RWE) is no longer optional for medical device startups—it’s essential. By proving safety, efficacy, and performance in real-world settings, RWE offers a faster, more cost-effectiv
Explore how wearable medical devices are transforming healthcare. Discover emerging trends, key opportunities for startups, strategies to overcome regulatory challenges, and tips for securing funding. Learn how innovation in AI, therapeutic wearables, and user-centered design can position your startup for success in this growing market.
Master the art of medical device startup funding. Discover expert strategies for securing venture capital, government grants, crowdfunding, and strategic partnerships to scale your startup successfully.
Artificial Intelligence (AI) is transforming the medical device industry, offering startups unprecedented opportunities to revolutionize diagnostics, treatment, and patient care. However, these advancements come with challenges, including navigating complex regulatory landscapes and ensuring ethical AI practices. Explore how startups can leverage AI's potential while addressing compliance and data security concerns, paving the way for innovation that prioritizes patient safety and trust.
Building a medical device startup involves more than just having innovative technology; it also requires a deep understanding of the complex and ever-changing regulatory requirements. Although navigat
With recent updates to the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), compliance has become a complex yet essential landscape for medical device manufacturers. These regulations, designed to enhance safety and transparency, set strict guidelines for accessing the European market. This article highlights key compliance obligations for 2024, from device classification to technical documentation, clinical evaluation, and post-market surveillance. Dive in to understand how to navigate these frameworks and ensure your devices meet the latest EU standards.
In an era where technology rapidly intersects with healthcare, the medical device industry stands at the forefront of a significant transformation. The integration of Artificial Intelligence (AI) and automation in Post Market Surveillance (PMS) is redefining the paradigms of device monitoring and patient safety. This blog post delves into how AI-driven technologies are automating routine tasks, enhancing data analysis, and enabling predictive analytics in PMS. It highlights the efficiencies and advancements these innovations bring to the medical device sector, while also addressing the critical ethical considerations inherent in such a technological leap. As we explore the balance between innovation and responsibility, we find ourselves on the cusp of a new era in medical device safety and effectiveness, driven by the transformative power of AI.
The UK's MHRA unveils its roadmap for future medical device regulations, focusing on patient safety and technological innovation. This strategic plan sets a timeline for enhanced regulations by 2025, emphasizing stakeholder collaboration and international harmonization. As regulatory consultants, we are poised to guide industry professionals through these critical changes, ensuring compliance and innovation in the medical device sector.
In the complex realm of medical devices, the true measure of innovation lies beyond initial market entry. It resides in the vigilant and continuous monitoring of these devices once they are in the hands of healthcare providers and patients. This blog delves into the world of Post-Market Surveillance (PMS) – a critical, ongoing journey that intertwines technology, patient safety, and data-driven insights. Discover how PMS transcends regulatory compliance, emerging as a strategic tool that shapes the landscape of medical advancements and safeguards public health.
In an era where medical device regulations are constantly evolving, the revised MDCG 2021-27 document stands as a critical guide for importers and distributors in the European Union. This revision, focusing on Articles 13 & 14 of Regulation (EU) 2017/745 and Regulation (EU) 2017/746, brings clarity and new responsibilities within the EU medical devices sector. From enhanced verification obligations to stringent registration requirements in EUDAMED, these changes underscore the EU’s commitment to ensuring the highest safety and quality standards in medical devices. This blog post delves into the key revisions of the MDCG 2021-27 document, offering a comprehensive analysis and practical examples to aid professionals in navigating these regulatory updates. Understanding these changes is vital, not just for compliance, but for maintaining a competitive edge in the dynamic EU market
In a significant move to enhance patient safety, the UK government has introduced The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2023. This development mandates manufacturers to implement robust post-market surveillance plans, ensuring continual monitoring and reporting of medical device performance. As we delve into these regulatory changes, it becomes evident that they not only raise the bar for compliance but also signify a proactive approach to healthcare. This shift underscores the necessity for manufacturers to adapt and align with these heightened standards, reaffirming their commitment to safety in the dynamic medical device sector.
The UK is gearing up for a significant overhaul in medical device regulations, aiming to enhance patient safety and align with contemporary needs. Key changes include a phased approach to implementing the new regulatory framework, extended acceptance of CE marked devices to ease transition, and strengthened Post-Market Surveillance requirements for improved patient safety. This comprehensive reform, set to begin implementation from July 2025, underscores a collaborative effort between the government, industry stakeholders, and the medical devices community, ensuring a smooth transition for all involved. Stay informed about these pivotal changes with our latest insights
Understanding the Critical Role of the UK Responsible Person in Medical Device Regulation: For manufacturers outside the UK aiming to navigate the complex regulatory landscape of the British medical device market, appointing a UK Responsible Person (UKRP) is not just a requirement, but a strategic necessity. This blog post explores the pivotal responsibilities of the UKRP in ensuring compliance with the UK's distinct post-Brexit regulatory framework. From registering devices with the MHRA to maintaining essential compliance documentation, the UKRP is your indispensable ally in successfully introducing your medical devices to the UK market. Discover how selecting the right UKRP can be a game-changer in your regulatory strategy